Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03170180

Enrollment

Registered

2017-05-30

Start date

2017-03-01

Completion date

2021-12-28

Last updated

2022-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach Neoplasms

Brief summary

1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study. 2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib). 3. Drug sensitivity prediction software (IRCR-DReSS) will present level of sensitivity and patients will be treated with sensitive drugs. 4. Patients will be evaluated every 6 weeks.

Interventions

DRUGSunitinib

sunitinib 37.5mg daily

DRUGGefitinib

Gefitinib 250mg daily

DRUGImatinib

Imatinib 400mg daily

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* age\>-20 * metastatic gastric cancer * life expectancy \>-3 months * ascites and pleural effusion that can be drained * ECOG 0-2 * Proper organ function * Patients who will be enrolled in sunitinib, gefitinib, imatinib clinical trial

Exclusion criteria

* HBeAg, HCV, HIV (+) * Active infection * Uncontrolled systemic disease

Design outcomes

Primary

Measure	Time frame
response rate	2 years

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026